Cel Sci (CVM) Total Debt (2010 - 2018)

Cel Sci (CVM) posted Total Debt of $1.2 million for Q1 2018, up 34.54% sequentially from $874593.0 in Q4 2017.

Cel Sci (CVM) Total Debt (2010 - 2018) Analysis & Trends

Cel Sci has reported Total Debt for 7 years, with the latest figure at $1.2 million in Q1 2018.

Quarterly Total Debt changed N/A year-over-year to $1.2 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $1.2 million (changed N/A YoY) and the FY2017 annual result came in at $994258.0, changed N/A from the prior year.
Total Debt grew to $1.2 million in Q1 2018 per CVM's latest filing, from $874593.0 in the prior quarter.
Over five years, Total Debt peaked at $1.2 million in Q1 2018 and troughed at $325794.0 in Q2 2017.
A 3-year average of $895072.4 and a median of $994258.0 in 2017 frame the typical range for Total Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.34 Bn
10	Cel Sci	2.12 Mn	-4.42 Mn	-	-

Download Data